Drilldown: Medicines
Use the filters below to narrow your results.
generic:
Brivaracetam (1) ·
Buprenorphine (1) ·
Butorphanol (1) ·
Cannabidiol (1) ·
Cenobamate (1) ·
Clobazam (1) ·
Codeine (2) ·
Dextropropoxyphene (1) ·
Dihydrocodeine (1) ·
Eslicarbazepine (1) ·
Ethosuximide (1) ·
Ethylmorphine (1) ·
Felbamate (1) ·
Fenfluramine (1) ·
Fentanyl (1) ·
Fosphenytoin (1) ·
Hydrocodone (1) ·
Hydromorphone (1) ·
Isosorbide (dinitrate, mononitrate) (1) ·
Lacosamide (1) ·
Levorphanol (1) ·
Meperidine (1) ·
Methadone (1) ·
Nalbuphine (1) ·
Nitroglycerin (glyceryl trinitrate, GTN) (1) ·
Oxymorphone (1) ·
Papaverine (1) ·
Pentazocine (1) ·
Perampanel (1) ·
Phenobarbital (1) ·
Phenytoin (1) ·
Rufinamide (1) ·
Stiripentol (1) ·
Tapentadol (1) ·
Tiagabine (1) ·
Valproic acid (1) ·
Vigabatrin (1) ·
Zonisamide (1)
brand:
None (5) ·
(multiple, generic dominant) (1) ·
Aptiom (1) ·
Banzel (1) ·
Briviact (1) ·
Cerebyx (1) ·
Darvon (1) ·
Demerol (1) ·
Depakote (1) ·
Diacomit (1) ·
Dilantin (1) ·
Dilaudid (1) ·
Dolophine (1) ·
Duragesic (1) ·
Epidiolex (1) ·
Felbatol (1) ·
Fintepla (1) ·
Fycompa (1) ·
Gabitril (1) ·
Imdur (mononitrate ER), Isordil (dinitrate); generics; with hydralazine as BiDil for HFrEF in self-identified Black patients (1) ·
Luminal (1) ·
Nitrostat, Nitrolingual, NitroMist, Nitro-Bid, Nitro-Dur, Minitran, Rectiv (1) ·
Nubain (1) ·
Nucynta (1) ·
Onfi (1) ·
Opana (1) ·
Sabril (1) ·
Stadol (1) ·
Suboxone (1) ·
Talwin (1) ·
Vicodin (1) ·
Vimpat (1) ·
Xcopri (1) ·
Zarontin (1) ·
Zonegran (1)
classes: (Click arrow to add another value)
mechanism:
None (2) ·
AMPA receptor antagonist (1) ·
GABA enhancer; sodium channel blocker; histone deacetylase inhibitor (1) ·
GABA reuptake inhibitor (GAT-1 blocker) (1) ·
GABAA positive allosteric modulator (1) ·
GABAA positive allosteric modulator; lactate dehydrogenase inhibitor (1) ·
GABAA potentiator and direct activator (1) ·
Irreversible GABA-T inhibitor (1) ·
Kappa agonist; mu antagonist (1) ·
Kappa agonist; mu partial agonist (1) ·
Kappa agonist; mu partial agonist/antagonist (1) ·
Mu-opioid agonist; norepinephrine reuptake inhibitor (1) ·
Mu-opioid receptor agonist (4) ·
Mu-opioid receptor agonist; NMDA antagonist (1) ·
Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) ·
Mu-opioid receptor agonist; sodium channel blocker (1) ·
Mu/kappa/delta agonist; NMDA antagonist (1) ·
Multiple mechanisms; GPR55 antagonist; TRPV1 agonist (1) ·
NMDA antagonist; GABAA potentiator (1) ·
Partial mu-opioid agonist; kappa antagonist (1) ·
Phosphodiesterase inhibitor; calcium channel blocker (1) ·
Potent mu-opioid receptor agonist (3) ·
Prodrug of phenytoin; sodium channel blocker (1) ·
Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) ·
Serotonin releaser; sigma-1 agonist (1) ·
Slow-inactivation sodium channel enhancer; CRMP-2 ligand (1) ·
Sodium channel blocker (2) ·
Sodium channel blocker; GABAA positive allosteric modulator (1) ·
Sodium channel modulator (1) ·
Sodium/T-type calcium channel blocker; carbonic anhydrase inhibitor (1) ·
SV2A ligand (higher affinity than levetiracetam) (1) ·
T-type calcium channel blocker (1)
uses:
None (36) ·
Mild to moderate pain; cough suppression (low-dose). (1) ·
'"`UNIQ--vote-00000C0A-QINU`"', '"`UNIQ--vote-00000C0B-QINU`"', '"`UNIQ--vote-00000C0C-QINU`"', '"`UNIQ--vote-00000C0D-QINU`"', '"`UNIQ--vote-00000C0E-QINU`"' (1) ·
'"`UNIQ--vote-0000145E-QINU`"', '"`UNIQ--vote-0000145F-QINU`"', '"`UNIQ--vote-00001460-QINU`"' (1)
starting dose:
None (36) ·
Adult: 15–60 mg every 4 hours as needed. (1) ·
Isosorbide mononitrate ER: 30-60 mg PO once daily in the morning, titrate to 120-240 mg/d; isosorbide dinitrate IR: 5-20 mg PO TID with a 12-14 hour nitrate-free interval to prevent tolerance (1) ·
SL 0.3-0.6 mg every 5 minutes up to 3 doses for acute angina (call EMS if not resolved after the third); IV infusion 5-10 mcg/min titrated; transdermal patch 0.2-0.4 mg/hr for 12-14 hours daily (nitrate-free interval prevents tolerance) (1)
preparations:
None (36) ·
Mononitrate 10, 20 mg IR; 30, 60, 120 mg ER; dinitrate 5, 10, 20, 30, 40 mg IR and ER (1) ·
SL 0.3, 0.4, 0.6 mg tablets; lingual spray 0.4 mg/spray; ER 2.5-9 mg capsules; transdermal patch 0.1-0.8 mg/hr; 2% ointment; 0.4% rectal ointment; 5 mg/mL IV (1) ·
Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)
fda max:
routes:
onset:
duration:
halflife:
bioavailability:
None (36) ·
Highly route-dependent: SL bypasses first-pass; oral has extensive first-pass (used only for chronic ER preparations); transdermal predictable'"`UNIQ--ref-00000C10-QINU`"' (1) ·
Mononitrate ~100% (no first-pass; the principal advantage over dinitrate); dinitrate ~20%'"`UNIQ--ref-00001462-QINU`"' (1) ·
~50% (variable, CYP2D6-dependent for analgesic effect). (1)
pregnancy:
None (36) ·
Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) ·
Limited data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Used in obstetric emergencies (uterine relaxation, severe hypertension) when needed; otherwise limited routine use.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 39 results in range #1 to #39.
B
C
D
E
F
H
I
L
M
N
O
P
- Papaverine
- Pentazocine
- Perampanel
- Pharmacopedia:Pharmacogenomics sandbox/Codeine
- Phenobarbital
- Phenytoin